



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Date: 08.03.2022

To,
Corporate Relations Department
BSE Limited
Floor 25, P. J. Towers,
Dalal Street
Mumbai – 400 001

Corporate Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra - Kurla Complex, Dalal Street,
Bandra (E), Mumbai - 400 051. Mumbai - 400 001.

Dear Sir/ Madam,

Sub: Proposed sale of equity shares of Bafna Pharmaceuticals Limited by SRJR Life Science LLP, through open market sale for achieving minimum public shareholding.

In accordance with the requirements of Rule 19(2)(b) and 19A(5) of the Securities Contract (Regulation) Rule, 1957 and Regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with Para 2(a) and Para (3) of the SEBI circular No. SEBI/HO/CFD/ CMD/CIR/P/43/2018 dated February 22, 2018 ("**Circular**") in connection with manner of achieving minimum public shareholding, we wish to inform the following details with respect to the intention of SRJR Life Sciences LLP ("**Seller**"), member of our Promoter Group, for sale of equity shares ("**Equity Shares**") of Bafna Pharmaceuticals Limited (the "**Company**") held by it, as per the following details:

Sr. No.	Details of the events to be provided	Information of such event
1.	Intention of the Promoter/ Promoter Group to sell and the purpose for sale.	The Seller intends to sell Equity Shares of the Company as a step towards compliance of the requirements for the purpose of achieving minimum public shareholding under applicable law specified above.





BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN : L24294 TN1995PLC030698

2.	Details of the Promoter/Promoter Group, who propose to divest their shareholding	SRJR Life Sciences LLP, member of our Promoter Group of the Company
3.	Total number of shares and percentage of shareholding proposed to be divested	99357 (Ninety Nine Thousand Three Hundred and Fifty Seven) Equity Shares currently proposed to be divested representing [0.42] % of the total paid up equity share capital of the Company, of the face value of Rs.10/- each.
4.	Period within which the entire divestment process will be completed ("Period")	Beginning 09th March 2022 till the actual date of completion of sale of Equity Shares as mentioned in serial no. 3 above

Undertaking received from the persons belonging to the Promoter/Promoter Group pursuant to Para 3(b) of the Circular is enclosed herewith.

Thanking You,

Yours faithfully,

For Bafna Pharmaceuticals Limited

Jitendra Kumar Pal
Company Secretary and Compliance Officer



Encl.: As Above

08.03.2022

To

The Company Secretary & Compliance Officer

Bafna Pharmaceuticals Limited

299, Thambu Chetty Street

Chennai 600 001

Dear Sir,


Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".


This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.

For and on behalf of **SRJR Life Sciences LLP**



JYOTHI RAJU CHINTALAPATI ★

Designated Partner



08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.



MAHAVEER CHAND BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.

For and on behalf of **MAHAVEER CHAND BAFNA HUF**



MAHAVEER CHAND BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.



PARAS BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI /HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.

For and on behalf of **PARAS BAFNA HUF**


PARAS BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.


AMRIBAI BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.


SASIKALA BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.


CHETNA BAFNA

08-03-2022

To,
The Company Secretary & Compliance Officer
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Chennai 600 001
Dear Sir,

Sub: Undertaking in connection with the sale of equity shares of face value of Rs. 10 each ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") through an open market sale (such sale, the "Proposed Sale")

In connection with the aforesaid subject and in accordance with Para (3)(b) of SEBI Circular No SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("**SEBI Circular**"), dealing with manner of achieving minimum public shareholding, we undertake that:

"We, belonging to the Promoter and Promoter Group of the Company, shall not buy any Equity Shares in the open market on the dates on which the Equity Shares are being sold by SRJR Life Sciences LLP as specified in the notice to the Stock Exchange(s) for the purpose of achieving minimum public shareholding requirements".

This undertaking is issued to enable you to submit to Stock Exchange(s) along with the intimation in relation to the Proposed Sale, as required under applicable laws.


NAVIN BAFNA M